A high uric acid result, but no symptoms

By Nirbhay Agarwal · 19 August 2026 · 6 min read

A routine blood test comes back. Most of it is fine. One line is flagged: uric acid, high.

You have never had a gout attack. Nothing hurts, nothing is swollen, and you have no idea what to do with this. Search for it and you will find two confident and opposite answers — that it is an early warning demanding treatment, and that it is a meaningless number that should never have been measured.

The guidelines take a third position, and it is more interesting than either.

What the guideline says

The 2020 American College of Rheumatology guideline addresses this directly. Its recommendation is:

For patients with asymptomatic hyperuricemia (SU >6.8 mg/dL with no prior gout flares or subcutaneous tophi), we conditionally recommend against initiating any pharmacologic ULT (allopurinol, febuxostat, probenecid) over initiation of pharmacologic ULT.

And it explicitly extends that to people who also have chronic kidney disease, cardiovascular disease, kidney stones or high blood pressure — the groups where you might most expect an exception.

So: a recommendation against drug treatment. Note the word conditionally, though. In this guideline’s grading, conditional means the panel expects the right answer to differ between people, and that the decision should be made case by case rather than by rule. It is not the same as “this number does not matter.”

The arithmetic behind it

The reasoning is worth seeing, because it is not the usual hand-waving about overtreatment.

Randomised trials — designed to study cardiovascular outcomes, but which counted gout along the way — did show that urate-lowering therapy reduced new cases of gout over three years. The effect was real. It was just applied to a population where almost nothing happened either way: incident gout occurred in under 1% of the treated arm and 5% of the placebo arm.

Translated into the number that matters clinically, the guideline puts it plainly:

24 patients would need to be treated with ULT for 3 years to prevent a single (incident) gout flare.

Twenty-four people on a daily drug for three years to prevent one attack in one of them. And that is the benefit side; the other twenty-three get the cost, the monitoring and the small risk of adverse effects for nothing.

The observational data points the same way. Among people whose urate was above 9.0 mg/dL — substantially high — only 20% developed gout within five years. Four in five did not.

There is a second reason the panel was unmoved, which is that the case for treating urate to protect the kidneys did not survive being tested. In 2020 two randomised trials looked at whether allopurinol slows the decline of kidney function in chronic kidney disease. It did not. Kidney function fell at the same rate on allopurinol as on placebo. Whatever else urate is doing in kidney disease, lowering it with a drug did not change the trajectory.

Put together: most people with a high number will not get gout, treating them all is inefficient, and the hoped-for benefits beyond gout did not materialise when someone checked.

But it is not nothing

Here is where the “meaningless number” reading goes wrong.

Above roughly 6.8 mg/dL, urate stops staying dissolved and starts forming crystals. That is chemistry, not statistics — it does not wait for symptoms, and it does not require a diagnosis. In the analogy borrowed from a rheumatology editorial, a high level is snowfall. Crystal deposits are snow settling on a roof. Nothing hurts while it is snowing.

The guideline concedes this in its own definitions. Setting out who the asymptomatic recommendation applies to, it notes that patients “with evidence of monosodium urate monohydrate (MSU) deposition on advanced imaging may still be considered asymptomatic if they have not had a prior gout flare or subcutaneous tophi.”

Read that again. You can have visible crystal deposits in your joints and still count as asymptomatic, because the category is defined by whether you have had an event — not by whether anything is accumulating. The 20%-in-five-years figure describes the first, not the second.

So the honest reading of a high result with no symptoms is: it is snowing, and it may go on snowing for years before anything falls off the roof. The guideline’s recommendation is not that this is fine. It is that for most people, a daily drug is too much intervention for that particular risk — a judgement about proportionality, not about whether the process is real.

What to actually do with the result

Four things, none of them dramatic.

Do not treat it by reflex, and do not chase the number down. Whatever else you take from this, “my urate is high so I should be on allopurinol” is not what the guideline says, and the trial evidence is against it. This is a conversation to have, not a conclusion to reach.

Find out why it is high. A urate result does not arrive in isolation. It travels with kidney function, blood pressure, blood sugar, weight, alcohol, and — very commonly — with medications. Thiazide diuretics for blood pressure and low-dose aspirin both raise urate; the guideline has recommendations about both, including that low-dose aspirin should not be stopped when it is being taken for a good reason. Losartan, if you need a blood pressure drug anyway, is conditionally preferred because it lowers urate as a side effect. Those are far more useful conversations than the number in isolation.

Have it measured again. A single reading is a single reading. Urate moves with hydration, recent meals, alcohol, illness and weight change. What matters is whether it is persistently high and which way it is trending — the same principle as the number that actually matters, applied before there is a diagnosis rather than after.

Know what changes the answer. The recommendation against treatment is for people with no prior flares and no tophi. The moment either of those appears, you are in a different part of the guideline entirely, and one where the recommendations get considerably stronger. Even a first flare shifts things: the panel conditionally recommends against starting treatment after a first attack in general, but conditionally recommends for it if you also have stage 3+ kidney disease, a urate above 9.0 mg/dL, or kidney stones.

The short version

A high uric acid result with no symptoms means the conditions for crystal formation are present. It does not mean you have gout, and it does not mean you need a drug — for most people the numbers do not justify one.

What it does mean is that this is now a thing to keep an eye on rather than a thing to forget, and that the useful response is a repeat test, a look at what else is going on, and a record of where the number sits over time.

If it ever does turn into gout, arriving at that appointment with three years of readings instead of one is worth a great deal.

Gout Journal is written by someone who lives with gout, not by a clinician. This article is general information, not medical advice — never start, stop or change a medication without talking to your own doctor.